Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis

[1]  R. D. Buck,et al.  2MD (DP001), a Single Agent in the Management of Hemodialysis Patients: A Randomized Trial , 2016, American Journal of Nephrology.

[2]  H. DeLuca,et al.  Use of 2MD, a Novel Oral Calcitriol Analog, in Hemodialysis Patients with Secondary Hyperparathyroidism , 2016, American Journal of Nephrology.

[3]  H. DeLuca,et al.  Novel, Selective Vitamin D Analog Suppresses Parathyroid Hormone in Uremic Animals and Postmenopausal Women , 2014, American Journal of Nephrology.

[4]  C. A. Dyer.  Safety and tolerability of paricalcitol in patients with chronic kidney disease , 2013, Expert opinion on drug safety.

[5]  L. Ong,et al.  Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism , 2013, Nephrology.

[6]  Y. Solak,et al.  Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study , 2012, Renal failure.

[7]  N. Mittman,et al.  Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. , 2010, Kidney international. Supplement.

[8]  Z. Massy,et al.  Vitamin D levels and early mortality among incident hemodialysis patients. , 2008, Kidney international.

[9]  H. DeLuca,et al.  New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 with conformationally restricted side chains: evaluation of biological activity and structural determination of VDR-bound conformations. , 2007, Archives of biochemistry and biophysics.

[10]  Alex J. Brown,et al.  Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[11]  M. Hernán,et al.  Activated injectable vitamin D and hemodialysis survival: a historical cohort study. , 2005, Journal of the American Society of Nephrology : JASN.

[12]  K. Martin,et al.  Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. , 2004, Seminars in nephrology.

[13]  H. DeLuca,et al.  2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 Potently Stimulates Gene-specific DNA Binding of the Vitamin D Receptor in Osteoblasts* , 2003, Journal of Biological Chemistry.

[14]  M. Wolf,et al.  Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.

[15]  Alex J. Brown,et al.  New vitamin D analogs. , 2003, Kidney international. Supplement.

[16]  D. Batlle,et al.  Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. , 2003, Kidney international.

[17]  H. DeLuca,et al.  A potent analog of 1α,25-dihydroxyvitamin D3 selectively induces bone formation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Brandi,et al.  Pharmacokinetics of 1,25(OH)2D3 and 1α(OH)D3 in normal and uraemic men , 2002 .

[19]  H. DeLuca,et al.  New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. , 1998, Journal of medicinal chemistry.

[20]  E. Slatopolsky,et al.  A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  B. Carroll,et al.  Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. , 1994, Kidney international.

[22]  A. Levin,et al.  Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. , 2007, Kidney international.

[23]  L. Brandi,et al.  Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  H. DeLuca,et al.  A highly sensitive method for large-scale measurements of 1,25-dihydroxyvitamin D. , 1998, Analytical biochemistry.